HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kao

This article was originally published in The Rose Sheet

Executive Summary

Japanese firm's consumer products sales increased 2.9% to $6.45 bil. (¥1=$.01), a 3.9% increase excluding currency, during the fiscal year ended March 31, Kao says. In North American and Europe, sales of John Frieda hair care products "increased substantially," fueled by new product launches, while the Bioré skin care brand grew as a result of repositioning efforts, firm claims. The brands helped drive consumer products sales in those regions up 4.6% to nearly $1 bil. Kao's reported net sales increased 3.8% to $8.75 bil., a 4.8% increase excluding the effect of currency. Net income was up 10.4% to $673.9 mil. For the fiscal year ending March 31, 2006, firm forecasts sales will rise 2.5% to $8.97 bil., and net income is projected to grow 2.5% to $691.4 mil...

You may also be interested in...



Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.

Medicare-For-Hmmm: A Year Of House Hearings Show Democratic Disunity

Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.

UsernamePublicRestriction

Register

RS012999

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel